VolitionRx Ltd Files 8-K on Officer/Director Changes
Ticker: VNRX · Form: 8-K · Filed: Sep 30, 2024 · CIK: 93314
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes, financial-statements
Related Tickers: VNRX
TL;DR
VolitionRx filed an 8-K detailing board and officer changes, plus financial exhibits.
AI Summary
VolitionRx Limited filed an 8-K on September 30, 2024, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits.
Why It Matters
Changes in a company's board of directors and executive officers can signal shifts in strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing is routine and reports on corporate governance and financial statements without indicating immediate operational or financial distress.
Key Players & Entities
- VolitionRx Limited (company) — Registrant
- September 30, 2024 (date) — Date of Report
FAQ
What specific items are covered in this 8-K filing by VolitionRx Limited?
This 8-K filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements of certain officers, as well as financial statements and exhibits.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is September 30, 2024.
In which state was VolitionRx Limited incorporated?
VolitionRx Limited was incorporated in Delaware.
What is the IRS Employer Identification Number for VolitionRx Limited?
The IRS Employer Identification Number for VolitionRx Limited is 91-1949078.
What is the business address of VolitionRx Limited?
The business address of VolitionRx Limited is 1489 West Warm Springs Road, Suite 110, Henderson, Nevada 89014.
Filing Stats: 1,318 words · 5 min read · ~4 pages · Grade level 11.3 · Accepted 2024-09-30 16:21:28
Key Financial Figures
- $0.001 — ich Registered Common Stock, par value $0.001 per share VNRX NYSE American, LLC
- $45 million — for Accelerated Innovation, deploying a $45 million fund, which invested in multiple platfo
- $1 billion — have gone on to raise or exit for over $1 billion. Dr. Rubin also currently serves, on a
- $10,840 — r services, Dr. Rubin shall receive (i) $10,840 per calendar quarter commencing Septemb
Filing Documents
- vnrx_8k.htm (8-K) — 34KB
- vnrx_ex991.htm (EX-99.1) — 13KB
- 0001477932-24-006038.txt ( ) — 175KB
- vnrx-20240930.xsd (EX-101.SCH) — 6KB
- vnrx-20240930_lab.xml (EX-101.LAB) — 14KB
- vnrx-20240930_cal.xml (EX-101.CAL) — 1KB
- vnrx-20240930_pre.xml (EX-101.PRE) — 9KB
- vnrx-20240930_def.xml (EX-101.DEF) — 2KB
- vnrx_8k_htm.xml (XML) — 4KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release of VolitionRx Limited Regarding Appointment of Director, dated September 30, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VOLITIONRX LIMITED Date: September 30, 2024 By: /s/ Cameron Reynolds Cameron Reynolds Chief Executive Officer & President 4 EXHIBIT INDEX Exhibit Number Description 99.1 Press Release of VolitionRx Limited Regarding Appointment of Director, dated September 30, 2024. 5